Elizabeth Bonifas
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,923 of the $6,595 with a category attached, or 89.8%. It is spread thinly across 29 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,349, 2.2 times the $1,068 reported in 2022. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 324 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$775
- Sanofi$668
- Regeneron Healthcare Solutions, Inc.$566
- Incyte Corporation$399
- Novartis$374
- plus $3K from 23 others
What the payments were for
- Food & beverage$5,92390%
- Education$67310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $1,271 |
| Johnson & Johnson | 22 | $775 |
| Sanofi | 26 | $668 |
| Regeneron Healthcare Solutions, Inc. | 29 | $566 |
| Incyte Corporation | 20 | $399 |
| Novartis | 22 | $374 |
| UCB, Inc. | 14 | $361 |
| E.r. Squibb & Sons, L.L.C. | 18 | $327 |
| Lilly USA, LLC | 18 | $301 |
| LEO Pharma Inc. | 10 | $218 |
| Sun Pharmaceutical Industries Inc. | 7 | $210 |
| Boehringer Ingelheim | 7 | $162 |
| Pfizer | 9 | $160 |
| Amgen | 8 | $159 |
| Dermavant Sciences, Inc. | 6 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Genentech USA, Inc. | 4 | $77 |
| Arcutis Biotherapeutics, Inc. | 4 | $71 |
| Galderma Laboratories, L.p. | 3 | $59 |
| Verrica Pharmaceuticals Inc. | 2 | $44 |
| Organon | 2 | $40 |
| Almirall LLC | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| Organogenesis Inc. | 1 | $21 |
| Journey Medical Corporation | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Biofrontera Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$100
How this compares
$6,595 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 58 | $221,999 |
| Fluorouracil | 59 | $4,328 |
| Fluocinonide | 33 | $2,347 |
| Betamethasone Dipropionate | 66 | $1,769 |
| Triamcinolone Acetonide | 259 | $1,721 |
| Ketoconazole | 123 | $1,260 |
| Hydroxyzine Hcl | 126 | $1,140 |
| Clobetasol Propionate | 14 | $706 |
| Clindamycin Phosphate | 28 | $600 |
| Nystatin | 46 | $569 |
| Doxycycline Hyclate | 33 | $354 |
| Mupirocin | 50 | $332 |
| Azithromycin | 49 | $197 |
| Paroxetine Hcl | 12 | $95 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $53 |
Paid to pharmacies, not to this prescriber.
Other family in Lima
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.